UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☑ EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☐ EXCHANGE ACT OF 1934 Commission File Number: 001-37702 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 95-3540776 (State or other jurisdiction of (I.R.S. Employer incorporation or orga ...

Summary of Amgen Inc. Conference Call Company Overview - **Company**: Amgen Inc. (NASDAQ: AMGN) - **Event**: Goldman Sachs 44th Annual Global Healthcare Conference - **Date**: June 14, 2023 - **Participants**: Robert Bradway (Chairman and CEO), Salveen Richter (Goldman Sachs) Key Points Industry Context - The healthcare and biopharma sectors are experiencing significant regulatory scrutiny, particularly regarding mergers and acquisitions, as evidenced by the FTC's move to block Amgen's acquisition of Horizon Therapeutics [2][3][4]. Acquisition of Horizon Therapeutics - Amgen remains optimistic about the acquisition, asserting that there are no anti-competitive issues that should prevent the merger [3][4]. - The company is preparing for a hearing in autumn 2023 to present its case against the FTC's concerns [3][6]. - Amgen expects the deal to close by mid-December 2023, pending the outcome of the hearing [5][6]. TEPEZZA Sales Performance - TEPEZZA sales have been weaker than anticipated, but Amgen remains confident in the product's potential and is actively working to expand its market presence [9][10][12]. - Data shows a significant benefit of TEPEZZA in chronic disease patients, with a 62% efficacy rate compared to 7% for placebo [12]. Biosimilars Business - Amgen has successfully launched AMJEVITA, a biosimilar, and is positioned as a leader in the biosimilars market [14][15]. - The company has launched six biosimilars and plans to launch five more, expecting to double its biosimilars business compared to 2021 levels [15][17]. - Amgen emphasizes the importance of being among the first to launch biosimilars to capture market share [14][16]. Hematology/Oncology Portfolio - The hem/onc business is performing well, driven by strong data supporting the efficacy of its products, particularly BLINCYTO [25][26]. - BLINCYTO is noted for its potential to improve outcomes in leukemia patients, and the company is excited about its subcutaneous formulation [26][27]. - Other products in the portfolio, such as Vectibix and KYPROLIS, are also showing strong performance [27]. Long-term Guidance and Growth - Amgen has reiterated its long-term guidance, citing strong growth in in-line products and international markets [30][32]. - The company reported a 20% volume growth in Europe and 35-36% in the Japan-Asia region [32]. - Amgen is optimistic about its pipeline, including potential breakthroughs in cancer therapies and treatments for cardiovascular diseases [33][54]. Challenges and Regulatory Environment - The Inflation Reduction Act is viewed negatively by Amgen, as it may hinder innovation and affect patient access to new therapies [46][47]. - Price pressure in the pharmaceutical industry is expected to continue, necessitating operational efficiency [57][58]. Innovation and AI Integration - Amgen is leveraging AI and machine learning to enhance its research capabilities and improve drug development processes [60][62]. - The company is focused on using human genetic data to inform its drug development strategies [61]. Capital Allocation Strategy - Amgen's capital allocation strategy includes investing in innovation, returning capital to shareholders, and paying down debt incurred from the Horizon acquisition [64]. Additional Insights - Amgen is committed to addressing unmet medical needs, particularly in oncology and rare diseases, and is excited about the potential of its innovative therapies [52][54]. - The company is adapting to regulatory changes and market dynamics while maintaining a focus on long-term growth and patient care [48][49].

Amgen Inc. (NASDAQ:AMGN) 4th Annual Oncology Innovation Summit: Insights for ASCO & EHA May 31, 2023 11:00 AM ET Company Participants David Reese - Executive Vice President of R&D Arvind Sood - Vice President of Investor Relations Conference Call Participants Yaron Werber - TD Cowen Yaron Werber Okay. Good morning, everybody. We're just going to wait five seconds or so to let everybody scroll in. And then we will get started. So good morning, everybody, and thank you once again for joining us at the 4th Ann ...

Amgen Inc. (NASDAQ:AMGN) BofA Securities 2023 Health Care Conference May 9, 2023 11:00 AM ET Company Participants Peter Griffith - CFO Dave Reese - EVP, R&D Conference Call Participants Dan Lundquist - Ban of America Dan Lundquist Hello. Good morning, everybody. Thank you for coming out to Las Vegas for the 2023 Healthcare Conference. You are at the first session with Amgen. I'm very pleased today to be joined by Peter Griffith, the CFO; and Dave Reese, Executive VP of R&D, here on stage today. We do have a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☑ EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☐ EXCHANGE ACT OF 1934 Commission File Number: 001-37702 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 95-3540776 (State or other jurisdiction of (I.R.S. Employer incorporation or org ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37702 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 95-3540776 (State or other jurisdiction of (I.R.S. Employer incorporation or organizat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q or (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37702 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 95-3540776 (State or other jurisdiction of incorporation or organization)(I. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q or (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37702 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 95-3540776 (State or other jurisdiction of incorporation or organization)(I.R.S. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37702 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 95-3540776 (State or other jurisdiction of incorporation or organization)(I.R.S. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |----------------------------------------------------------------------------|------------------------------------------| | Amgen Inc. (Exact name of registrant as specified in | c ...